

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

DR. REDDY'S LABORATORIES, LTD.
AND DR. REDDY'S LABORATORIES, INC.,
Petitioners,

v.

INDIVIOR UK LIMITED
(F/K/A RB PHARMACEUTICALS LIMITED),
Patent Owner.

Case No. IPR2016-01113

Patent No. 8,475,832

PATENT OWNER INDIVIOR UK LIMITED'S UPDATED EXHIBIT LIST

LIST OF EXHIBITS

Exhibit	Description
2001	Redline comparison of Teva IPR2016-00280 Petition and Dr. Reddy's IPR2016-01113 Petition
2002	Redline comparison of Teva IPR2016-00280 Declaration of Dr. Das and Dr. Reddy's IPR2016-01113 Declaration of Dr. Celik
2003	<i>Dr. Reddy's to acquire product portfolio from TEVA for US Market</i> , Press Release, Dr. Reddy's Laboratories Ltd., June 11, 2016
2004	Email from Dr. Reddy's counsel summarizing meet and confer teleconference conducted July 6, 2016
2005	Teva/Allergan Divestiture Products Table, Docket No. C-4589 (F.T.C. July 27, 2016)
2006	<i>FTC Requires Teva to Divest Over 75 Generic Drugs to Settle Competition Concerns Related to its Acquisition of Allergan's Generic Business</i> , Press Release, Federal Trade Commission (July 27, 2016), https://www.ftc.gov/news-events/press-releases/2016/07/ftc-requires-teva-divest-over-75-generic-drugs-rival-firms-settle
2007	PTAB Telephonic Conference Transcript, IPR2016-01111, IPR2016-01112, IPR2016-01113 (August 1, 2016)
2008	Carl O'Donnell, <i>Teva Pharm finalizing asset sales to clear Allergan deal - source</i> , Reuters (May 5, 2016), http://www.reuters.com/article/allergan-ma-teva-pharm-ind-assets-idUSL2N1820VD
2008	Carl O'Donnell, <i>Teva Pharm finalizing asset sales to clear Allergan deal - source</i> , Reuters (May 5, 2016), http://www.reuters.com/article/allergan-ma-teva-pharm-ind-assets-idUSL2N1820VD
2009	Nandita G. Das & Sudip K. Das, <i>Development of Mucoadhesive Dosage Forms of Buprenorphine for Sublingual Drug Delivery</i> , 11 Drug Delivery 89 (2004)
2010	Priya Batheja <i>et al.</i> , <i>Basic Biopharmaceutics of Buccal and Sublingual Absorption</i> , in <i>Enhancement in Drug Delivery</i> 175, 182 (Elka Tountou & Brian W. Barry eds. 2006)
2011	David S. Weinberg <i>et al.</i> , <i>Sublingual absorption of selected opioid analgesics</i> , 71 <i>Clinical Pharmacology & Therapeutics</i> 335 (1988)
2012	John Mendelson <i>et al.</i> , <i>Bioavailability of Sublingual Buprenorphine</i> , 37 <i>J. Clinical Pharmacology</i> 31 (1997)

2013	Jinsong Hao & Paul W.S. Heng, <i>Buccal Delivery Systems</i> , 29(8) Drug Development & Industrial Pharmacy 821 (2003)
2014	S.A. Robertson, <i>PK-PD modeling of buprenorphine in cats: intravenous and oral transmucosal administration</i> , 28(5) Journal of Veterinary Pharmacology and Therapeutics 453 (2005)
2015	Yamamoto <i>et al.</i> , <i>Absorption of water-soluble compounds with different molecular weights and [Asu^{1.7}]-eel calcitonin from various mucosal administration sites</i> , 76 J. Controlled Release 363 (2001)
2016	Amir H. Shojaei, <i>Buccal Mucosa as a Route for Systemic Drug Delivery: A Review</i> , 1(1) J. Pharmacy & Pharmaceutical Sci. 15 (1998)
2017	Rakesh Hooda <i>et al.</i> , <i>A Review on Oral Mucosal Drug Delivery System</i> , 1(1) Pharma Innovation 14 (2012)
2018	N.V. Satheesh Madhav, <i>Orotransmucosal Drug Delivery Systems: A Review</i> , 140 J. Controlled Release 2 (2009)
2019	U.S. Patent No. 7,331,251
2020	Swatantra K.S. Kushwaha <i>et al.</i> , <i>Advances in Nasal Trans-Mucosal Drug Delivery</i> , 1(7) J. Applied Pharmaceutical Sci. 21 (2011)
2021	Javier O. Morales & Jason T. McConville, <i>Manufacture and Characterization of Mucoadhesive Buccal Films</i> , 77 Eur. J. Pharmaceutics and Biopharmaceutics 187 (2011)
2022	Thakur Smriti, <i>Mouth Dissolving Films: A Review</i> , 4(1) Int'l J. Pharma and Bio Sciences P-899 (2013)
2023	Heiko Tietgen, <i>Physicochemical Properties, in Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays</i> 399 (Hans Gerhard Vogel <i>et al.</i> eds., 2006)
2024	Ulrika Espefalt Westin, <i>Olfactory Transfer of Analgesic Drugs After Nasal Administration</i> (Dissertation, Uppsala University 2007)
2025	Ulrike Werner, <i>In Situ Gelling Nasal Inserts for Prolonged Drug Delivery</i> (Dissertation, Free University Berlin 2003)
2026	Email correspondence between counsel for Patent Owner & Petitioner, September 8-9, 2016

Date: September 14, 2016

Respectfully submitted,

By 

Andrea G. Reister

Registration No. 36,253

Enrique D. Longton

Registration No. 47,304

COVINGTON & BURLING LLP

One CityCenter, 850 Tenth Street, NW

Washington, DC 20001

(202) 662-6000


Attorneys for Patent Owner

CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. § 42.6, I hereby certify that on this 14th day of September 2016, the foregoing Patent Owner Indivior UK Limited's Updated Exhibit List, together with Exhibit 2026, was served by electronic mail, by agreement of the parties, on the following counsel of record for petitioner.

Jeffrey B. Arnold (jarnold@cantorcolburn.com)
Peter R. Hagerty (phagerty@cantorcolburn.com)
Leslie-Ann Maxwell, Ph.D. (amaxwell@cantorcolburn.com)
Andrew C. Ryan (ryan@cantorcolburn.com)
Cantor Colburn LLP

Date: September 14, 2016


Andrea G. Reister, Esq.
Registration No.: 36,253